Aurobindo Pharma Financial Statements

Aurobindo Pharma (AUROPHARMA) reported revenue of ₹323.46B in FY2025 with net income of ₹34.86B. Total assets stood at ₹497.85B and free cash flow was ₹19.57B.

Aurobindo Pharma Income Statement

Hover the chart icon for year-over-year change.

FY 2021 – FY 2025

Item	Chart	2021	2022	2023	2024	2025
Revenue		247.75B	237.76B	251.46B	295.59B	323.46B
Cost of Rev. Cost of Revenue		-99.02B	-101.40B	-112.93B	-126.03B	-130.26B
Gross Profit		148.72B	136.36B	138.53B	169.56B	193.19B
SGA Sales, General & Admin		-95.39B	-89.28B	-98.43B	-105.56B	-121.15B
Op. Income Operating Income		42.78B	35.81B	27.65B	48.79B	55.55B
PBT Profit Before Tax		73.99B	34.04B	26.24B	43.97B	50.66B
Net Income		53.33B	26.47B	19.28B	31.69B	34.86B
Dil. Shares Diluted Shares		585.93M	586.00M	585.87M	585.85M	582.87M
Diluted EPS		91.01	45.19	32.90	54.16	59.81

Figures in ₹ — millions (M), billions (B), trillions (T). EPS is earnings per share.

Understanding the Income Statement

The income statement shows Aurobindo Pharma's revenue and expenses over a period. Revenue minus costs gives gross profit; after operating expenses, interest, and taxes, the remainder is net income. Diluted EPS divides net income by all shares that could exist if options and convertibles were exercised.

Aurobindo Pharma Balance Sheet

Hover the chart icon for year-over-year change.

FY 2021 – FY 2025

Item	Chart	2021	2022	2023	2024	2025
Curr. assets Total current assets		198.24B	181.23B	215.46B	242.06B	271.62B
Non-curr. assets Total non-current assets		140.30B	157.99B	183.44B	208.66B	226.23B
Total assets		338.54B	339.22B	398.90B	450.72B	497.85B
Curr. liabilities Total current liabilities		106.65B	81.56B	114.94B	121.99B	146.82B
Non-curr. liab. Total non-current liabilities		12.60B	11.92B	15.44B	30.22B	24.56B
Total liabilities		119.25B	93.48B	130.38B	152.21B	171.38B
Total equity		219.29B	245.74B	268.52B	298.51B	326.47B
Total liab. & eq. Total liabilities & equity		338.54B	339.22B	398.90B	450.72B	497.85B

Figures in ₹ — millions (M), billions (B), trillions (T).

Understanding the Balance Sheet

The balance sheet captures Aurobindo Pharma's financial position at a point in time — what it owns (assets), what it owes (liabilities), and the residual value to shareholders (equity). Total assets always equals total liabilities plus equity.

Aurobindo Pharma Cash Flow Statement

Hover the chart icon for year-over-year change.

FY 2021 – FY 2025

Item	Chart	2021	2022	2023	2024	2025
Net Income		73.44B	33.73B	26.13B	43.80B	50.66B
Operating CF Cash flow Operating Activities		33.29B	50.16B	23.87B	24.35B	39.25B
Capex Investments in PPE		-18.74B	-20.53B	-24.04B	-27.80B	-19.68B
Investing CF Cash flow Investing Activities		5.99B	-32.12B	-39.78B	-42.56B	-18.76B
Dividend Paid		-2.34B	-2.64B	-4.40B	-2.64B	-10.40M
Financing CF Cash flow Financing Activities		-13.65B	-29.69B	18.14B	8.00B	1.20B
Cash (start) Cash at beginning of period		27.47B	53.30B	41.63B	43.92B	33.85B
Cash (end) Cash at end of period		53.30B	41.63B	43.92B	33.85B	55.64B
FCF Free Cash Flow		14.55B	29.64B	-170.50M	-3.46B	19.57B

Figures in ₹ — millions (M), billions (B), trillions (T).

Understanding Cash Flow

The cash flow statement tracks how Aurobindo Pharma's cash moves through operations, investing, and financing activities. Free cash flow — operating cash minus capital expenditure — shows what is available to return to shareholders.

Data from audited consolidated filings. For educational purposes only — not investment advice. Last update: Mar-2025